UNSPSC 51343003: Tipranavir

This classification denotes a protease inhibitor with the molecular formula C31H33F3N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZZT404XD09, chemically known as 2-pyridinesulfonamide, n-(3-((1r)-1-((6r)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2h-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)- but generally known as tipranavir, which bears US NIH Compound Identifier 65027. European Medicines Agency schedules Tipranavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04883MIG.

UNSPSC 51343003 Tipranavir, a Commodity code, identifies antiretroviral pharmaceutical products for state and local procurement; however, the recent solicitation records tagged to this code show little alignment with the code's nominal scope. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for antibiotic pharmaceuticals (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) rather than tipranavir, and Seminole County, Florida released an IFB on June 30, 2026, for naloxone and drug deactivation systems—neither purchase is tipranavir or an HIV protease inhibitor. The misalignment suggests state and local procurement systems may be applying this commodity code to broader pharmaceutical categories or that the tagging reflects administrative consolidation across related drug product lines rather than category-specific purchasing patterns.

Recent activity under the code is sparse and geographically dispersed. Illinois Department of Public Health and Seminole County represent the only named issuing bodies in the recent-opportunities block. The Illinois award was a piggyback IFB through a consortium vehicle (MMCAP Infuse) with a 12-month initial term and renewal options through year three; Seminole County's procurement was a traditional competitive IFB with an initial two-year term and one-year renewal option, targeting quarterly deliveries. Neither opportunity is open for new bidders. If tipranavir or other HIV treatment pharmaceuticals appear in state and local procurement, they are not visible in the current records under this commodity code.